![ECOG-ACRIN logo[19516]275×75](https://blog.ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
August 31, 2026
Insights on a new breast cancer treatment study, concerns about low uptake of genomic testing, and a preview of the Fall Group Meeting
August 31, 2026
This phase 3 clinical trial for patients with soft tissue sarcoma is comparing chemotherapy before surgery versus surgery alone
August 31, 2026
This phase 2 clinical trial is testing two variations of the triplet combination of azacitidine, venetoclax, and gilteritinib compared to standard therapy
August 31, 2026
Guidance for a zero embargo mandate from the National Institutes of Health that aims to accelerate free public access to research results
August 31, 2026
A Standing Main Member of ECOG-ACRIN since 2012
August 31, 2026
The latest findings in breast cancer and smoking cessation support during cancer treatment
August 31, 2026
Timely information about research presented at medical meetings, recognition of research leaders, and more
August 25, 2026
This trial is evaluating a new immunotherapy approach for patients with high-risk multiple myeloma that has returned after initial treatment